Evotec

Drug toxicity is a leading cause of failure in development. Early toxicity identification can change that. At Cyprotex, we use advanced in vitro models to identify safety risks early— ensuring the safest compounds reach the clinic. Learn more about our services here: hubs.ly/Q03bgjld0

Get in touch to discuss your project at enquiries@cyprotex.com

#theadmetoxspecialists #cyprotex #toxicology

A deep understanding of ADME is essential for successful drug discovery and development. Now updated with the latest ICH M12 guidelines, the 6th edition of Cyprotex’s ADME Guide is here for you to explore more.

Join thousands of scientists who rely on this must-have resource for optimizing compound design and development.

Download your free copy today! hubs.ly/Q038XPjm0

#cyprotex #theadmetoxspecialists

Drug-drug interactions (DDIs) are a major concern in drug development, and staying compliant with evolving regulatory guidelines is more critical than ever. 4th edition of Cyprotex’s DDI Guide breaks down the impact of the latest ICH M12 guidelines on your DDI studies — helping you navigate with clarity and confidence.

#cyprotex #theadmetoxspecialists

Meet the Evotec team at #SLAS2025 hubs.ly/Q032Zcxm0

Dirk Winkler, SVP #HitIdentification, will be presenting on #AI #ML integration and its value in accelerating #DrugDiscovery.

Schedule a meeting with Dirk at booth #850 by contacting info@evotec.com.

Meet our team at booth #805 and learn about our research at #SLAS2025. hubs.ly/Q032dfq60.

Mélanie Carquin PhD, Team Leader in Evotec’s HTP Biology & Screening group, will be presenting research on RNA #SplicingModulators and their role in drugging ‘undruggable’ targets.